Planned Maintenance: Some services may turn out to be unavailable from 15th January, 2026 to 16th January, 2026. We apologize for the inconvenience!

4HZL image
Deposition Date 2012-11-15
Release Date 2013-05-01
Last Version Date 2024-11-20
Entry Detail
PDB ID:
4HZL
Keywords:
Title:
Neutralizing antibody mAb#8 in complex with the Epitope II of HCV E2 envelope protein
Biological Source:
Method Details:
Experimental Method:
Resolution:
2.85 Å
R-Value Free:
0.27
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 43 21 2
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:E2 envelop protein
Chain IDs:C (auth: E), F
Chain Length:17
Number of Molecules:2
Biological Source:Recombinant Hepatitis C virus H77(5'UTR-NS2)/JFH1_V787A,Q1247L
Polymer Type:polypeptide(L)
Molecule:Fab heavy chain
Chain IDs:A (auth: H), D (auth: A)
Chain Length:222
Number of Molecules:2
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Fab light chain
Chain IDs:B (auth: L), E (auth: B)
Chain Length:217
Number of Molecules:2
Biological Source:Mus musculus
Primary Citation
Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus.
Proc.Natl.Acad.Sci.USA 110 7418 7422 (2013)
PMID: 23589879 DOI: 10.1073/pnas.1305306110

Abstact

Hepatitis C virus (HCV) envelope glycoprotein E2 has been considered as a major target for vaccine design. Epitope II, mapped between residues 427-446 within the E2 protein, elicits antibodies that are either neutralizing or nonneutralizing. The fundamental mechanism of antibody-mediated neutralization at epitope II remains to be defined at the atomic level. Here we report the crystal structure of the epitope II peptide in complex with a monoclonal antibody (mAb#8) capable of neutralizing HCV. The complex structure revealed that this neutralizing antibody engages epitope II via interactions with both the C-terminal α-helix and the N-terminal loop using a bifurcated mode of action. Our structural insights into the key determinants for the antibody-mediated neutralization may contribute to the immune prophylaxis of HCV infection and the development of an effective HCV vaccine.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback